An Anticoagulant Dermatan Sulfate Proteoglycan Circulates in the Pregnant Woman and Her Fetus

Maureen Andrew,* Lesley Mitchell,* Leslie Berry,* Bosco Paes,* Michael Delorme,* Frederick Ofosu,† Robert Burrows,§ and Bashir Khambalia*

Departments of *Pediatrics, †Pathology, and §Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada L8N 3Z5

Abstract

Investigation of the in vitro ability of plasma from pregnant women to inhibit exogenous thrombin (25 nM) demonstrated that heparin cofactor II inhibited more thrombin (3.0±0.7 nM, mean±SD) than plasma from women 3–5 d postpartum (1.9±0.5 nM) or plasma from nonpregnant adults (1.5±0.4 nM). Levels of heparin cofactor II were only slightly increased over normal in both pregnant and postpartum women and did not account for the observed increase in thrombin bound to heparin cofactor II. Assay of pregnancy plasma for dermatan sulfate anticoagulant activity demonstrated the presence of activity equivalent to 0.23±0.02 µg/ml of porcine mucosal dermatan sulfate. This activity could not be demonstrated in normal adult plasma or plasma from women on the contraceptive pill. The mass of dermatan sulfate in pregnancy and umbilical cord plasmas was increased over adult control plasma by 0.20 µg/ml (53%) and 0.29 µg/ml (76%), respectively. The glycosaminoglycan-containing fraction of plasma was isolated and an assay for anticoagulant dermatan sulfate confirmed its presence in both pregnancy and cord plasmas but minimal activity in adult plasma. Gel chromatography of isolated fractions from both pregnancy and cord plasmas revealed a polydisperse, active species with apparent Mr 150,000 D. Reductive elimination decreased the apparent Mr of the active species on gel chromatography to 31,000 D for cord and 21,000 D for pregnancy products. This confirmed the presence of an anticoagulant active dermatan sulfate proteoglycan circulating in the plasmas of pregnant women at term and fetuses at delivery. (J. Clin. Invest. 1992. 89:321–326.) Key words: glycosaminoglycan • heparin cofactor II • perinatal • thrombin

Introduction

Pregnancy is a unique physiologic state with profound changes in the hemostatic system. Fibrinolytic activity is markedly impaired primarily resulting from increases in inhibitors of plasminogen activators (1–3). In contrast, the plasma concentrations of most procoagulants, especially fibrinogen (1), factor VIII (1), von Willebrand factor (1), and factor VII activity (4) are increased in plasmas of pregnant women. The levels of most inhibitors of coagulation are not altered or only slightly increased (1, 5–8) but protein S is decreased (9). The net result of the altered coagulation system is that thrombin may be generated in increased amounts in normal pregnancy (10–12) compared to nonpregnant adults. The regulation of thrombin action on factors V and VIII is key to the control of coagulation (13) and, if uncontrolled, enhanced thrombin generation could lead to thrombosis. Indeed, pregnancy (including the postpartum period) has been considered to be a “hypercoagulable state” because there is an increased incidence of thromboembolic complications during this period (14, 15). However, during late pregnancy, the incidence of thrombosis is lower than one would predict from the altered venous hemodynamics created by the gravid uterus (16). In fact, one analysis showed there was no higher incidence of thromboembolic complications in pregnancy than in the normal population but a fivefold higher incidence in the postpartum period (17).

The hemostatic system of the fetus and newborn is in a dynamic and immature state evolving towards the adult system (18). During normal labor and delivery, there is activation of the fetal coagulation system with thrombin generation (19). Yet, healthy infants do not develop thromboembolic complications despite physiologically low levels of antithrombin III (AT III)1, heparin cofactor II (HC II), protein C, and protein S. Further, infants with inherited homozygous protein C deficiency are relatively protected in utero but develop life-threatening thromboembolic complications in the postpartum period (20).

We describe herein the results of investigations into the ability of plasmas from pregnant women and fetuses to inhibit thrombin and characterization of a naturally occurring anticoagulant, the presence of which may help to explain some of the above observations.

1. Abbreviations used in this paper: AT III, antithrombin III, DS, dermatan sulfate; GAG, glycosaminoglycan; HC II, heparin cofactor II; α2M, α2-macroglobulin.
Porcine mucosal dermalan sulfate (DS; MF 701, Batch 48) was obtained from Mediolanum Pharmaceutici, Milan, Italy. Chondroitin ABC lyase (EC 4.2.2.4) and chondroitin AC lyase (EC 4.2.2.5) were obtained from ICN Biomedicals Canada Inc., Mississauga, ON, and were reconstituted in a buffer of 0.15 M NaCl and 0.01 M sodium acetate. Ancrod (EC 3.4.21.28) was from Connaught Laboratories, Toronto, ON. Sepharose CL-4B and Sephadex G-200 were from Pharmacia, Uppsala, Sweden, and Hyflo Super-Cel was from Fisher Scientific Co., Toronto, ON. Alcian blue 8 GX, dimethylsulfoxide, and the non-specific protease, Pronase E (Streptomyces griseus), were purchased from Sigma Chemical Co., St. Louis, MO. Cellulose acetate strips (Sepaphore III) were from Gelman Sciences, Inc., Ann Arbor, MI. An assay for dermatan sulfate anticoagulant assay (Stachrom DS) was from Diagnostica Stago, Asnières, France. Purified human thrombin was a kind gift of Dr. J. W. Fenton II, Albany, NY. Antiserum to AT III, HC II, and α2-macroglobulin (α2M) were from Atlantic Antibodies, Scarborough, ON; Behring, Hoechst, Montreal, PQ; and DAKO (Dimension Lab), Burlington, ON, respectively.

**Methods**

**Plasma samples.** Paired blood samples were obtained, with informed consent, from 17 consecutive women with normal pregnancies within 24 h before elective caesarean section and 3–5 d postpartum. Blood was collected into 3.8% sodium citrate (9:1 blood/citrate) and plasma obtained by centrifugation at 1,700 g for 15 min. Plasmas from 16 nonpregnant adults served as control. These were used for quantification of thrombin inhibition by SDS-PAGE (see below) and DS anticoagulant activity. Cord plasmas were obtained consecutively from healthy newborns after uncomplicated delivery. Subsequently, plasma pools from a number of groups of at least 10 individuals each (women at 6, 16, and 30 wk gestational age, pregnant women at term, women on oral contraceptive pills, nonpregnant adults, and cords) were used for DS anticoagulant assay. Assays for DS anticoagulant activity were also performed on individual samples from a separate group of 10 pregnant women, 10 women postpartum, and 10 nonpregnant adults (five women, five men). Pooled plasmas were used for purification of glycosaminoglycan (GAG) containing material (see below).

**Thrombin–inhibitor complex formation.** The contributions of AT III, HC II, and α2M to the inhibition of exogenous thrombin were determined as previously described (21). In brief, plasma samples were defibrinated with ancord. In some experiments, defibrinated plasma was reacted with chondroitin ABC or AC lyase (final concentration 0.3 U/ml) for 1 h at 37°C. Selectivity of these enzymes has been previously demonstrated (22). 125I-Thrombin was added to the plasma samples (final concentration 25 nM) and incubated at 37°C for 90 s. The proportion of thrombin complexed by each inhibitor was the same at 30, 45, 60, and 90 s in both pregnancy and nonpregnant adult plasmas (data not shown) and the 90-s time point was chosen for convenience. The reaction was stopped by sampling into 3 vol of SDS sample buffer (5% mercaptoethanol, 10% glycerol, 0.06 M Tris-HCl, 0.01% bromophenol blue, pH 6.8) and heating in a boiling water bath for 2 min. The samples (~10,000 cpm per lane) were subjected to SDS-PAGE on a 4% stacking gel and 3–15% gradient running gel. Gels were stained with 0.1% Coomassie Blue R250 in 40% methanol/10% acetic acid, destained in 40% methanol/10% acetic acid, and dried onto filter paper. Autoradiography was carried out and the amount of thrombin bound by each inhibitor measured by quantitative densitometric scanning. The positions of the thrombin–inhibitor complexes were determined by performing the same procedure in plasma deficient in AT III or immunodepleted of α2M, or in plasma to which heparin or DS had been added. Inhibitor concentrations in plasma were measured by immunoelectrophoresis (HC II) or radial immunodiffusion (AT III, α2M).

**DS mass assay.** Plasma pools were treated with chondroitin AC lyase (final concentration 0.025 U/ml) for 5 h at 37°C. Aliquots were then reacted with chondroitin ABC lyase (final concentration 0.05 U/ml) or an equal volume of enzyme buffer for 5 h at 37°C. The resulting samples were treated with 1.0 mg/ml Pronase E while dialyzing against 0.1 M Tris-HCl, 0.002% sodium azide, pH 7.5 for 48 h. Every 12 h, an additional 0.5 mg/ml of protease was added to the reaction. The product was pressure dialyzed against water to a volume of ~1 ml and centrifuged 15 min in an Eppendorf centrifuge (Brinkmann Instruments, Westbury, NY). The supernatants were dried on cellulose polyacrylate strips. The spots were stained with 0.025% alcian blue 8 GX/25% ethanol/10% acetic acid and destained in 40% methanol/10% acetic acid. Each spot was suspended in 1 ml of dimethylsulfoxide and the absorbance measured at 678 nm. The difference between the two absorbances (chondroitin ABC lyase and buffer treated) was compared to a standard curve of porcine mucosal DS of known mass concentration. Porcine mucosal DS was fully recovered when added to adult plasma and subjected to this technique. This staining technique has been shown to be sensitive and selective for staining of GAG (23).
Purification and characterization of plasma DS. In that it was possible that the plasma DS was present as a proteoglycan, the above procedure was modified to preserve proteins. Pooled plasmas were mixed with 2/3 vol of saturated ammonium sulfate and stirred at 23°C for 1 h. This mixture was centrifuged at 4,000 g for 15 min and the supernatant was dialyzed against 0.15 M NaCl. This material was warmed to 37°C and mixed thoroughly with 10% cetylpyridinium chloride to a final concentration of 1% and kept at 4°C overnight. The precipitated cetylpyridinium chloride was redissolved by warming to 20°C. The material was then centrifuged at 23°C at 4,000 g for 20 min and the supernatant was removed. The pellet was resuspended in one-fifth original plasma volume of 3 M NaCl at 45°C and three-fifths original plasma volume of cold ethanol/0.0058 M sodium acetate was quickly added. The mixture was kept at 4°C overnight then centrifuged at 4,000 g for 20 min at 4°C. The supernatant was removed and the pellet resuspended in one-fifth original plasma volume of water and again precipitated with three-fifths original plasma volume of cold ethanol/sodium acetate. This was centrifuged at 4,000 g for 20 min at 4°C. The pellet was freeze-dried and resuspended in 1 ml of 1 M NaCl. After centrifugation in an Eppendorf centrifuge, the supernatant was collected and the pellet washed with a small volume of 1 M NaCl. The supernatant and washings were dialyzed against 0.15 M NaCl and assayed for DS anticoagulant activity. The yield of anticoagulant active DS from this procedure was 40–70%.

The isolated material was subjected to gel chromatography on Sephrose CL-4B (1.0 × 49 cm) in 1 M NaCl. Fractions of 1.2 ml were collected and consecutive fractions were pooled in groups of two, freeze-dried, reconstituted in 0.5 ml of water, dialyzed against 0.15 M NaCl, and assayed for DS anticoagulant activity. Purified material was also subjected to reductive elimination by reaction of 0.5 ml of material with 0.055 ml 2 M KOH for 3 h at 23°C, and then 0.1 ml of 200 µM NaBH₄/0.1 M NaOH was added and incubated for a further 17 h. This was neutralized with 14 µl of 50% acetic acid. The product was subjected to gel chromatography on Sephadex G-200 (1.0 × 49 cm) in 1 M NaCl. Fractions of 1.2 ml were collected, and consecutive fractions were pooled in groups of three and freeze-dried, reconstituted in 0.5 ml of water, dialyzed against 0.15 M NaCl, and assayed for DS anticoagulant activity. Dextran or dextran sulfates of known average molecular weight were used as standards on both columns to estimate molecular weight. In addition, purified material was added to normal adult plasma to achieve an activity level equivalent to 0.4 µg of porcine mucosal DS/ml. Thrombin–inhibitor complex formation in this mixture was measured as above.

Statistics. Groups were compared using a paired (for pre- and post-delivery samples) or unpaired one-sided t test with P < 0.05 considered significant.

Results

Thrombin–inhibitor complex formation. The concentration of thrombin–HC II complexes (Fig. 1) was higher in the plasmas of pregnant women before delivery (3.0±0.7 nM, mean±SD) than 3–5 d postpartum (1.9±0.5 nM, P < 0.01). The latter plasma was similar to pooled adult plasma (1.5±0.4 nM). The amounts of thrombin bound to other inhibitors are shown in Table I.

The simplest explanation for this observation would be a change in HC II levels. However, the HC II level in this group of women was 1.35±0.09 U/ml (mean±SEM) predelivery compared with 1.16±0.07 U/ml (P > 0.05) postdelivery. In the nonpregnant adult pool, the level was 0.90±0.06 U/ml. Thus, a difference in HC II levels did not completely account for the observed increase in thrombin inhibition. We hypothesized that there was some other substance present in pregnancy plasma which catalyzed the thrombin–HC II interaction. In cord plasma, low levels of HC II made this assay too insensitive to detect significant differences in binding of thrombin to HC II.

DS assays. By assay of the mass of DS present in plasma, it was found that pooled pregnancy plasma contained 0.58±0.02 µg/ml (mean±SEM), cord plasma 0.67±0.03 µg/ml, and normal adult plasma 0.38±0.05 µg/ml of DS (Table II). Plasma pooled from eight pregnant women at term contained DS anticoagulant activity equivalent to 0.23±0.02 µg (mean±SEM) of porcine mucosal DS/ml of plasma. This activity was abolished by treatment with ABCase but not ACCase or enzyme buffer. No activity was detectable in pooled nonpregnant adult plasmas or in plasmas pooled from women on oral contraceptive pills and women at 6, 16, and 30 wk of gestation.

Subsequently, individual anticoagulant assays on 10 pregnant women at term and 10 women 3 d postpartum were performed. These showed that all pregnant women had measurable activity (0.19±0.1 µg/ml, mean±SD). Postpartum plasmas demonstrated lower levels (0.09±0.09 µg/ml, P < 0.01) with 4 of the 10 plasmas having no detectable activity. Activity

| Table I. Concentration of Thrombin-Inhibitor Complexes in Pregnant and Nonpregnant Patients after In Vitro Addition of Thrombin |
|-----------------|-----------------|-----------------|-----------------|
|                 | AT III          | HC II           | α₂ M            |
| Predelivery     | (n = 17)        | 10.2±1.2        | 3.0±0.7         | 3.7±0.8         |
| Postpartum      | (n = 17)        | 11.9±1.0        | 1.9±0.5*        | 3.3±0.8         |
| Nonpregnant     | (n = 16)        | 11.9±1.2        | 1.5±0.4*        | 2.7±1.2         |

Thrombin–inhibitor complex concentration after reaction of 125I-thrombin with plasma (final concentration 25 nM) for 90 s. Quantitation was performed using scanning densitometry after SDS-PAGE of the plasma/thrombin mixture and autoradiography. Concentration is expressed as mean±SD.

* Significantly different from predelivery value (P < 0.05).
Summary of anticoagulant activity and mass assays for DS in cord and pregnancy plasma. Anticoagulant activity is based on a chromogenic, HC II–dependent antithrombin assay. Mass assay is based on alcin blue 8 GX binding to glycosaminoglycan resistant to degradation by chondroitin AC lyase but sensitive to chondroitin ABC lyase. Values for activity and mass are expressed as mean±SEM or estimates of activity (in parentheses) based on yield and activity of purified material.

* Significantly different from normal pool (P < 0.05).

was abolished in all cases by ABCase but not ACase. In comparison, activity was not measurable in 10 nonpregnant adults.

DS activity could not be accurately measured in cord plasma as some fraction in the plasma (likely bilirubin) interfered with absorbance readings at 405 nm. Therefore, partial purification was undertaken of cord and nonpregnant adult pooled plasmas. When corrected for yield (determined by mass assay), the DS activity in cord plasma was ~ 0.2 µg/ml. As noted above, no DS activity was detected in plasma from nonpregnant adults. Following the same purification technique used for cord plasma, activity was detected in the concentrate of nonpregnant adult plasma which, when corrected for yield, was 0.03 µg/ml in the original plasma. This is below the sensitivity of the DS anticoagulant activity assay in a plasma system.

Characterization of plasma DS. Gel chromatography of material isolated from both pregnancy and cord plasmas on Sepharose CL-4B yielded similar results. A single, somewhat polydisperse peak of anticoagulant activity was seen with a Kav of 0.67 (Fig. 2). After reductive elimination, chromatography on Sephadex G-200 was again similar and demonstrated a peak with Kav of 0.54 for pregnancy and 0.40 for cord.

After addition of material isolated from pregnancy plasma, thrombin complexes with HC II were increased over nonpregnant adult control and decreased to baseline with chondroitin ABC lyase treatment but not chondroitin AC lyase. Similarly, when material isolated from cord plasma was added to adult plasma, increased HC II–thrombin complexes were noted which decreased to baseline with chondroitin ABC lyase but not chondroitin AC lyase (data not shown).

Discussion

There are profound changes in the hemostatic system during normal pregnancy that lead to thrombin generation, fibrin deposition, and fibrinolysis within the placenta or at the uteroplacental junction (10–12, 25, 26). Localized fibrin deposition is important for the establishment and possibly repair of the placenta (27, 28). However, uncontrolled thrombin generation in the uteroplacental unit could lead to systemic thrombosis, particularly in the late stages of pregnancy when there is marked impairment of deep venous blood flow.

We have noted an increase in thrombin inhibition by HC II in plasmas from pregnant women at term. Though these women had slightly increased levels of HC II, consistent with previous reports (6, 7), this was insufficient to completely account for the observation since postpartum HC II concentrations were not significantly different from antepartum yet, postpartum there was less contribution of HC II to thrombin complex formation. We hypothesized that a substance was present which catalyzed the thrombin–HC II reaction. This was confirmed in a HC II-dependent antithrombin assay in both pregnancy plasma and in partially purified material from cord plasma.

Several GAGs are capable of catalyzing the thrombin–HC II reaction including heparin, heparan sulfate, DS, and very high levels of chondroitin-4-sulfate and chondroitin-6-sulfate (29). None of the subjects had received heparin. In the plasmas from pregnant women, thrombin inhibition by AT III was not increased, thus, endogenous heparan sulfate could not be the catalyzing substance since it primarily catalyzes thrombin–AT III formation. The catalyzing activity was abolished by ABCase, but not ACase, in all instances. Thus, this activity was attributable to DS rather than chondroitin-4 - or -6-sulfate.

The presence of DS in the plasma of healthy adults has been shown previously (30). Extrapolating from the total GAG content of serum (31), the amount of DS expected would be ~ 0.20–0.25 µg/mL. The value for adult pooled plasma by our mass assay method is in reasonable agreement with these reports. However, the DS normally present in adult plasma had little catalytic activity. In contrast, the increment in total DS mass in pregnancy and cord plasma over adult plasma agrees well with the measured activity. It appears that most of the increase in DS mass is anticoagulant active DS.

Purification of GAG containing material from pregnancy and cord plasmas revealed that the active DS present was similar in both. The Kav on Sepharose CL-4B corresponds to an average Mr of 150,000 D. This is much larger than typical DS GAG chains, suggesting that the substance was a proteoglycan rather than free GAG. This was confirmed by the decrease in Mr of the active fraction after reductive elimination which cleaves the O-linked GAG chains from the core protein of a proteoglycan.
Thus, we have identified a DS proteoglycan in the plasmas of pregnant women obtained immediately before delivery and in cord blood at delivery. This DS proteoglycan is capable of catalyzing the inhibition of thrombin by HC II. We were unable to detect this material in plasmas from healthy nonpregnant adults, women on oral contraceptive pills, or pregnant women at up to 30 wk of gestation. We have not yet studied in detail the period from 30 wk of gestation to term to determine when this first appears.

DS proteoglycans are a family of proteoglycans which are ubiquitous in the extracellular matrix of connective tissue (32) and serve multiple functions (33). During pregnancy, the placenta (34) and uterus (35) are rich in DS proteoglycan. The mechanism by which this DS proteoglycan might appear in blood is unknown. The rapid decrease in activity postpartum suggests that this is an effect of pregnancy and that the activity may be of placential origin. The source of the DS proteoglycan in the fetus is also speculative. However, we have previously shown, in an animal model, that DS-like activity is found in the fetal circulation after administration of a low-molecular weight heparin (36) to the mother, indicating that there is a pool of DS which can be released into the fetal circulation.

Anticoagulant activity has been previously isolated from the placenta (37, 38) and from cord blood (39). The anticoagulant activity from placenta was shown to be secondary to a protein which binds phospholipid and does not inhibit thrombin (37, 40), clearly distinguishing it from the substance we have isolated. In addition, it has not been shown to circulate in the blood. The activity isolated from cord blood demonstrated “heparin-like” thrombin inhibition. Further characterization showed that it did not act through AT III (41) and the original observation was attributed, in part, to a fetal fibrinogen. This may have also represented DS activity which would not have been appreciated since the presence of HC II was not known at that time. Circulating anticoagulant GAG molecules have been noted in some pathologic conditions (42–45). To our knowledge, this is the first demonstration of this phenomenon in physiologic states.

The ability of DS to enhance thrombin inhibition by HC II has only recently been described (46). It has led to the investigation of DS as an antithrombotic agent (47–50) in animal models. These have shown it to be effective with less bleeding side effects than heparin. Thus, the finding of an active DS proteoglycan in pregnancy and in cord blood of newborn infants is of interest. Its presence may partly explain the low risk of thrombosis in pregnant women and fetuses when there is increased thrombin generation. Because it falls rapidly after delivery, it might also provide an explanation for the increased incidence of thrombosis in the puerperium. Further studies on the site of origin, time course of appearance, and physiological relevance of the measured levels are needed to clarify its role.

Acknowledgments

The authors acknowledge the staffs of the Coagulation Laboratory and Labour and Delivery Unit, St. Joseph’s Hospital, Hamilton, Ontario for sample collection and processing and Dr. M. W. C. Hatton for reviewing the manuscript.

This work was supported by a grant from Physicians Services Incorporated and the Medical Research Council of Canada. Dr. Andrew is a Career Scientist of the Heart and Stroke Foundation of Ontario. Dr. Delorme is a Research Fellow of the Heart and Stroke Foundation of Canada.

References


